Abstract. Prostaglandin i 2 (Pgi 2 ) agonist has been reported to reduce tumor metastasis by modifying tumor angiogenesis; however, the mechanisms of how Pgi 2 affects the endothelial cells or pericytes in tumor vessel maturation are still unclear. the purpose of this study was to clarify the effects of Pgi 2 on tumor metastasis in a mouse lung metastasis model using lewis lung carcinoma (llc) cells. the mice were treated continuously with beraprost sodium (BPS), a Pgi 2 analog, for 3 weeks and then examined for lung metastases. the number and size of lung metastases were decreased significantly by BPS treatment. in addition, scanning electron microscopy and immunohistochemistry revealed that BPS increased the number of tumor-associated pericytes and improved intratumor hypoxia. collectively, this study suggests that BPS attenuated vascular functional maturation in metastatic tumors.
Introduction
Prostaglandin i 2 (Pgi 2 ) is an important vascular prostanoid that provides an important balance in tumor angiogenesis (1, 2) . Honn et al were the first to demonstrate that PGI 2 strongly reduced the number of lung tumor metastases using an artificial lung metastasis model (3) . Since the initial reports of the anti-metastatic action of Pgi 2 and its analogs, a wide variety of tumor cell lines have been studied in models of artificial metastasis (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . However, the relationship between Pgi 2 -prostacyclin receptor (iP) signaling and tumor angiogenesis, including endothelial cells and pericyte interaction, remains to be clarified.
tumor blood vessels are structurally and functionally abnormal, in that they lack the normal hierarchical arrangement of arterioles, capillaries, and venules (16) . tumor endothelial cells are often loosely connected to each other and are covered by fewer and more abnormal mural pericytes (16) (17) (18) . in clinical data, low pericyte coverage of tumor blood vessels is related to poor patient prognosis (19) (20) (21) , and pericyte dysfunction is suggested to increase metastasis (22) . our recent studies have revealed novel effects of Pgi 2 on its target cells, such as endothelial and endothelial progenitor cells (23) , which suggested that Pgi 2 -iP signaling attenuates vascular maturation through endothelial and pericyte interaction. in this study, we evaluated whether activation of Pgi 2 -iP signals of tumor blood vessels by a stable Pgi 2 analog, beraprost sodium (BPS), enhanced pericyte adhesion to endothelial cells, induced maturation of tumor blood vessels, decreased hypoxic areas in the metastatic tumors, and resulted in suppression of lung metastasis in lung cancer.
Materials and methods
Lung cancer cell line and reagents. lewis lung carcinoma (llc; non-small cell lung cancer derived from c57Bl/6 mice) cells were purchased from american type culture collection (Manassas, Va, uSa) and maintained at 37˚C in 5% co 2 using rPMi-1640 medium (life technologies, grand island, ny, uSa) containing 2 mM l-glutamine, 50 u/ml penicillin, and 50 µg/ml streptomycin, supplemented with 10% fetal bovine serum (complete medium). BPS was provided by toray industries, inc. (chiba, japan). Immunohistochemistry. α-SMa (abcam, cambridge, uK) and ng2 (Millipore, Billerica, Ma, uSa) as pericyte markers and endomucin (Santa cruz Biotechnology, inc., Santa cruz, ca, uSa) as an endothelial cell marker were studied by immunofluorescence to evaluate angiogenesis in metastatic lung tumors. Hypoxic areas were evaluated by a Hypoxyprobe-1 kit. Zinc-fixed lung specimens were sectioned (4 µm thickness), mounted onto slides, and air-dried for 30 min. the sections were deparaffinized in xylene and rehydrated via a series of graded alcohols. the slides were rinsed with PBS, and antigen retrieval was enhanced by microwaving in 10 mM citrate buffer pH 6.0 for 20 min. they were incubated in 1% bovine serum albumin + PBS-t (triton) for 20 min at room temperature and then incubated overnight at 4˚C with a 1:100 dilution of rabbit anti-mouse α-SMa, 1:200 dilution of rabbit anti-mouse ng2, or 1:50 dilution of Mab1 (mouse monoclonal anti-pimonidazole antibody). they were rinsed with PBS and then incubated for 1 h with a goat anti-rabbit alexa fluor 488 antibody (diluted 1:1,000) or a donkey anti-mouse alexa fluor 488 antibody (diluted 1:1,000) at room temperature. Slides were rinsed with PBS, incubated for 20 min in 1% bovine serum albumin + PBS-t, and then incubated with a 1:50 dilution of rat anti-mouse Endomucin at 4˚C overnight. Slides were rinsed with PBS and then incubated for 1 h with a rabbit anti-rat alexa fluor 594 antibody (diluted 1:500) at room temperature. after rinsing, slides were incubated with Hoechst 33258 (diluted 1:1,000; invitrogen life technologies, carlsbad, ca, uSa) for 30 min at room temperature. Slides were mounted with fluoromount (Diagnostic Biosystems, Pleasanton, ca, uSa) to prevent fluorescent bleaching.
Quantification of lung metastasis. excised mouse lungs were fixed in zinc fixative (BD Biosciences Pharmingen, inc., San Diego, ca, uSa) and embedded in paraffin. Tumor metastasis to the lungs was assessed by hematoxylin and eosin (H&e) staining. light photomicrographs of the left lobe of the lungs were taken at magnification, x40 (5 visual fields/section and 5 sections/mouse) using a light microscope (BX51; olympus, tokyo, japan). the number of metastatic nodules was counted, and the metastatic area was quantified using ImageJ software (niH, Bethesda, MD, uSa).
DDw-and BPS-treated mice within an experimental set (5 mice/group) were analyzed with the same threshold and results as reported below. tumors were selected at random from each slide (4 tumors/mouse and 5 mice/group) at magnification, x200 observed with a fluorescence microscope (BX51; olympus). the tumor area, number of endomucin . the area of hypoxia was analyzed as described below. tumors observed with a fluorescence microscope were selected at random from each slide (4 tumors/mouse and 2 mice/group) at original magnification, x200. The tumor area and area of MAb1 + cells in each tumor were quantified by ImageJ software. The result is reported as the ratio of hypoxic area to tumor area.
Scanning electron microscopy. tissue preparation for scanning electron microscopy, the potassium hydroxide (KoH) digestion method was descr ibed previously (24). anesthetized control and treated mice were perfused with physiological saline followed by a mixture of 0.5% glutaraldehyde (ga)-0.5% paraformaldehyde (Pfa) in 0.1 M phosphate buffer solution (PB), pH 7.4. after fixation by perfusion, lungs were cut and immersed in 2% ga in 0.1 M PB for 2 weeks at 4˚C. Then the tissue blocks were washed thoroughly with 0.1 M PB, immersed in 30% KoH solution for 8-10 min at 60˚C to remove the extracellular matrix around tumor blood vessels. after KoH-digested tissue blocks were rinsed five or six times in 0.1 M PB, they were conductively stained by treating with 1% tannic acid in 0.1 M PB (2 h, 20˚C) and 1% OsO 4 in 0.1 M PB (2 h, 20˚C). After conductive staining, the samples were dehydrated in graded ethanols, transferred to isoamyl acetate, and dried in a critical point dryer (HcP-2; Hitachi Koki co., ltd., tokyo, japan) using liquid co 2 . the dried samples were mounted onto a metal plate, coated with platinum-palladium using an ion-sputter coater (e1010; Hitachi Koki co., ltd.), and then observed with a field emission type scanning electron microscope (S-4100; Hitachi High-technologies corp., tokyo, japan).
Clonogenic growth assay. llc cells (1.5x10 3 cells) were incubated in 6-well plates for 24 h. Subsequently, growth medium was changed to complete medium containing the indicated concentrations of BPS. treated cells were incubated under normoxic condition for 10 days. after incubation, colonies in a 6-well plate were stained with 0.5% crystal violet (wako, osaka, japan) in 0.5% methanol. the number of colonies was determined by a colony counter and software (Microtec nition, chiba, japan).
Cell proliferation assay. we used Brdu assays [cell Proliferation eliSa, Brdu (colorimetric); roche, tokyo, japan] to assess cell proliferation. llc cells (3.0x10 3 cells) were incubated in 96-well plates. the next day, the medium was replaced by complete medium containing the indicated concentrations of BPS, and llc cells were incubated for 3 days. after a 3-day BPS treatment, the Brdu assay was performed according to the manufacturer's protocol. Brdu was added in the medium, and llc cells were incubated for 2 h. the Brdu-uptake in the treated cells was assessed using a microplate luminometer (Thermo Fisher Scientific, Waltham, Ma, uSa).
Antibody array. llc cells (2.5x10
3 cells) were incubated in 100 mm dishes for 24 h. Subsequently, the growth medium was changed to complete medium containing 0 or 10 nM BPS. treated cells were incubated under the normoxic condition for 4 days. after incubation, we measured the cytokine spectrum in the supernatants using the Proteome Profiler™ Mouse angiogenesis array kit (r&D Systems, Minneapolis, Mn, uSa), which detects 53 cytokines, chemokines, and growth factors simultaneously. array membranes were processed following the manufacturer's recommendations. the signal intensity was measured on the laS-3000 luminescence detector, and the resulting images were analyzed using Multi gauge (Version 2.2; both from Fujifilm, Tokyo, Japan). To compare the luminescence intensities of the samples, we subtracted the background staining and normalized the data to the positive controls on the same membrane.
Statistical analysis. the measurements are presented as means ± SeM. results were analyzed by Student's t-test using Microsoft excel. two-sided p<0.05 was considered to be statistically significant.
Results

BPS treatment reduces lung metastasis.
to evaluate the effect of BPS on lung metastasis, we employed an experimental lung metastasis model. after tumor cell inoculation, mice were treated with BPS for 3 weeks; then they were sacrificed, and lung metastases were counted in the H&e-stained lung sections. in control groups, tumors with wide-spread pleural dissemination of colonized metastases were observed, while tumors with randomly clustered small metastatic nodules were observed in the BPS-treated group (fig. 1a) . the median number of metastatic nodules in the BPS-treated groups was significantly reduced compared with that in the control group (13.8 vs. 21.0, respectively, p<0.05) (fig. 1B) . the median area of metastatic nodules in BPS-treated groups was significantly smaller than that in control groups (0.06 and 0.18/mm 2 , respectively, p<0.05) (fig. 1B) . these results suggest that administration of BPS significantly reduced the number of lung metastases in our mouse lung metastasis model.
BPS enhances pericyte and endothelial interaction in tumor
microvasculature. next, to evaluate vascular maturation through endothelial and pericyte interaction, we analyzed the structure of tumor blood vessels in the mouse metastatic tumors using scanning electron microscopy. in the BPS-treated group, pericyte bodies (green) attached to endothelial capillary tubes (red) along with processes, and the diameters of tumor blood vessels were decreased, while in the control group, pericytes were absent or loosely connected ( fig. 2a) .
to evaluate the effects of BPS on tumor angiogenesis, including pericyte association at the metastatic site, pericytes (α-SMa + or ng2 + cells) and endothelial cells (endomucin + cells) in the metastatic tumor site were analyzed by immunofluorescence (figs. 2B and 3a). in the control group, α-SMa + or ng2 + cells were mostly located randomly in the metastatic tumor sites, and they did not colocalize with endomucin + cells (figs. 2B and 3a), while in the BPS-treated group, α-SMa + or ng2 + cells coexisted regularly beside endomucin + cells, and most of these cells were merged with endomucin + cells (figs. 2B and 3a), which revealed that the number of mature pericytes had increased, and moreover, the number of endothelial-attached pericytes was increased compared with that in the control group (figs. 2c and 3B). these results suggested that BPS strongly enhanced pericyte and endothelial interaction in the tumor microvasculature.
BPS induces vascular functional maturation in metastatic
tumors. we hypothesized that functionally mature vasculature without hypoxic regions abrogate tumor metastasis because pericyte-covered endothelial cells are considered 'mature vasculature,' which is rarely observed in the tumor area. in order to evaluate the tumor vascular maturation, we measured hypoxia levels in the metastatic tumors by immunohistochemistry using pimonidazole as a hypoxia marker. Pimonidazole stained the on llc cells. the cell growth was assessed by the Brdu cell growth assay or clonogenic assay ( fig. 5a and B). in our results, BPS did not inhibit tumor growth. to examine the autocrine factors related to tumor angiogenesis, we analyzed the effects of conditioned media with or without BPS on llc cells using an antibody array that simultaneously detected the relative concentrations of 53 angiogenesis-related proteins ( fig. 5c ). in this assay, osteopontin, serpin e1, and McP-1 were elevated in both BPS-treated and untreated groups, but the change in these factors were not significant. Based on these results, BPS did not affect llc cell growth directly.
Discussion
in the present study, the number of lung metastases was significantly reduced by BPS treatment in our mouse model. Since the first report from Honn and colleagues demonstrating that Pgi 2 and its analogs strongly reduced the number of lung metastases (3), studies of the Pgi 2 effect on metastasis have been repeated using a wide variety of tumor cell lines (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Because multistep processes of metastasis formation are responsible for the tumor spread, the effect of BPS on tumors and the tumor microenvironment needs to be analyzed. Most studies have examined: ⅰ) tumor cell-induced platelet aggregation and its inhibition by Pgi 2 (5,6,28-30); ⅱ) prevention of endothelial cell retraction (31-33); ⅲ) modulation of immune systems (4,7) ; or ⅳ) direct inhibitory effects on tumor cells (25) (26) (27) . However, the mechanisms of tumor vessel maturation by Pgi 2 was not previously examined.
in this study, we demonstrated that BPS strongly enhanced pericyte and endothelial interaction in the tumor microvasculature, which is a novel anti-metastatic mechanism of a Pgi 2 analog. the present results suggested that BPS induced structural changes in tumor vessels and led to endothelial maturation, which is consistent with our previous results (34) . consequently, tumor vessel maturation was induced, and hypoxia levels in the metastatic tumors decreased, resulting in BPS-induced vascular normalization in the tumor microenvironment. these results seem paradoxical because improving circulation in the tumor leads to tumor shrinkage, but clinically used anti-angiogenic therapies that successfully target tumor vessels are believed to increase microenvironment-induced tumor shrinkage. Bevacizumab, an anti-angiogenic drug, is now used in combination with cytotoxic agent for vascular normalization.
in the analysis of immunohistochemistry, α-SMa + cells merged with endomucin + cells significantly increased in the BPS-treated group ( fig. 2c) , while ng2 + cells merged with endomucin + cells did not significantly increase in the BPS-treated group ( fig. 3B ). this result seems to be inconsistent. However, in general, it is known that α-SMa expresses in more mature status of pericytes than ng2 (35) , and BPS induced more mature pericytes in this study. the number of endothelial cells in the tumors increased in the BPS-treated group with or without pericytes (data not shown). these results indicate that BPS promotes the maturation of tumor blood vessels.
finally, to rule out the possibility of a direct tumor effect of BPS on llc cells, we investigated tumor growth inhibition by treatment of cultured cells with BPS at concentrations up to 1 µM. the angiogenic factors produced by llc cells themselves were not changed. these results suggested that BPS did not affect tumors directly, but affected the tumor microenvironment.
altering the tumor microenvironment by addition of Pgi 2 analogs that affect endothelium-pericyte interaction may yield strategies for targeted angiogenesis therapies. However, additional clinical studies are needed to clarify the potential benefits and risks associated with anti-metastatic treatment by Pgi 2 analogs.
